| 6.18 -0.26 (-4.04%) | 12-15 15:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.31 | 1-year : | 9.44 |
| Resists | First : | 7.11 | Second : | 8.09 |
| Pivot price | 6.37  |
|||
| Supports | First : | 5.55 | Second : | 4.61 |
| MAs | MA(5) : | 6.31 |
MA(20) : | 6.28 |
| MA(100) : | 7.32 |
MA(250) : | 0 | |
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 27.2 |
D(3) : | 30.9 |
| RSI | RSI(14): 45.2 |
|||
| 52-week | High : | 3500.41 | Low : | 5.55 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ACON ] has closed above bottom band by 36.1%. Bollinger Bands are 12.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.34 - 6.37 | 6.37 - 6.4 |
| Low: | 5.68 - 5.71 | 5.71 - 5.74 |
| Close: | 6.13 - 6.18 | 6.18 - 6.23 |
Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.
Sat, 06 Dec 2025
Aclarion (ACON) Price Target Increased by 15.00% to 23.46 - Nasdaq
Thu, 04 Dec 2025
Aclarion (Nasdaq: ACON) Nociscan case study guides targeted spine surgery - Stock Titan
Thu, 04 Dec 2025
Aclarion, Inc. Stock (ACON) Opinions on Nociscan Technology Publication - Quiver Quantitative
Tue, 02 Dec 2025
Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S. - The Globe and Mail
Thu, 20 Nov 2025
Aclarion (ACON) Sees Price Target Boost by Ascendiant Capital | ACON Stock News - GuruFocus
Wed, 12 Nov 2025
Aclarion, Inc. SEC 10-Q Report - TradingView — Track All Markets
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | -4 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 671370 (%) |
| Held by Institutions | 671330 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.65e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 258.79 |
| Profit Margin | 0 % |
| Operating Margin | -9 % |
| Return on Assets (ttm) | 666.1 % |
| Return on Equity (ttm) | -52.4 % |
| Qtrly Rev. Growth | 67480 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0.02 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 17420 |
| Forward Dividend | 36140 |
| Dividend Yield | 281877% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|